3,5-diarylazoles as novel and selective inhibitors of protein kinase D.
Bioorg Med Chem Lett 2011;
21:1447-51. [PMID:
21300545 DOI:
10.1016/j.bmcl.2011.01.014]
[Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2010] [Revised: 01/05/2011] [Accepted: 01/06/2011] [Indexed: 01/19/2023]
Abstract
The synthesis and preliminary studies of the SAR of novel 3,5-diarylazole inhibitors of Protein Kinase D (PKD) are reported. Notably, optimized compounds in this class have been found to be active in cellular assays of phosphorylation-dependant HDAC5 nuclear export, orally bioavailable, and highly selective versus a panel of additional putative histone deacetylase (HDAC) kinases. Therefore these compounds could provide attractive tools for the further study of PKD/HDAC5 signaling.
Collapse